Natera's Prospera Heart With DQS Cuts False Positives By Over 37%, Outperforming Dd-cfDNA Percentage Alone, AJT Publication Shows

Benzinga07:15 ET

Natera Reports Outcomes From Study of MRD Test for Soft Tissue and Bone Sarcomas

Yahoo FinanceMay 6 10:24 ET

Craig-Hallum Maintains Natera(NTRA.US) With Buy Rating

Moomoo NewsMay 6 03:33 ET · Ratings

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Envista Holdings (NVST) and Natera (NTRA)

TipRanksMay 5 09:20 ET · Ratings

Natera Announces Results of Signatera Study

TipRanksMay 5 07:15 ET

Express News | Natera's Signatera Shows 93% Sensitivity In Leiomyosarcoma, Most Common Sarcoma Subtype In Study

BenzingaMay 5 07:06 ET